Astera Labs (NASDAQ:ALAB) Shares Climb 6.8% – Should You Buy?

Posted by Anthony Miller on Nov 11th, 2026

Astera Labs, Inc. (NASDAQ:ALAB – Get Free Report)’s stock price rose 6.8% on Wednesday. The company traded as high as $237.76 and last traded at $230.91. 3,966,352 shares traded hands during mid-day trading, a decline of 23% from the average daily volume of 5,153,752 shares. The stock had previously closed at $216.18.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ALAB. Jefferies Financial Group increased their price objective on Astera Labs from $270.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Barclays boosted their target price on Astera Labs from $200.00 to $325.00 and gave the stock an “equal weight” rating in a report on Monday, July 20th. Morgan Stanley upped their target price on Astera Labs from $382.00 to $389.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. Needham & Company LLC lowered their price target on Astera Labs from $425.00 to $300.00 and set a “buy” rating on the stock in a report on Wednesday, November 4th. Finally, Susquehanna lowered their price target on Astera Labs from $310.00 to $258.00 and set a “neutral” rating on the stock in a report on Wednesday, November 4th. Thirteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, Astera Labs has an average rating of “Moderate Buy” and a consensus target price of $320.85.

Get Our Latest Report on Astera Labs

Astera Labs Stock Performance

The stock has a market cap of $40.36 billion, a price-to-earnings ratio of 92.00 and a beta of 3.86. The stock’s 50-day simple moving average is $297.39 and its two-hundred day simple moving average is $256.20.

Astera Labs (NASDAQ:ALAB – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.13. The company had revenue of $584.90 million for the quarter, compared to the consensus estimate of $550.78 million. Astera Labs had a return on equity of 25.35% and a net margin of 29.64%. The firm’s revenue was up 153.6% compared to the same quarter last year. During the same period last year, the business posted $0.49 earnings per share. As a group, research analysts predict that Astera Labs, Inc. will post 2.99 earnings per share for the current year.

Insider Activity

In other Astera Labs news, Director Stefan A. Dyckerhoff sold 8,994 shares of Astera Labs stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $211.41, for a total value of $1,901,421.54. Following the transaction, the director directly owned 1,987 shares of the company’s stock, valued at $420,071.67. The trade was a 81.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jitendra Mohan sold 90,630 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $340.35, for a total value of $30,845,920.50. Following the transaction, the chief executive officer owned 1,266,665 shares of the company’s stock, valued at approximately $431,109,432.75. This trade represents a 6.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 408,558 shares of company stock worth $126,050,884 over the last 90 days. Company insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On Astera Labs

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Greenleaf Trust raised its stake in Astera Labs by 1.8% during the 2nd quarter. Greenleaf Trust now owns 2,000 shares of the company’s stock valued at $966,000 after purchasing an additional 36 shares during the last quarter. Parkside Financial Bank & Trust grew its position in Astera Labs by 74.5% in the 2nd quarter. Parkside Financial Bank & Trust now owns 96 shares of the company’s stock worth $46,000 after purchasing an additional 41 shares during the last quarter. Integrated Advisors Network LLC grew its position in Astera Labs by 4.8% in the 3rd quarter. Integrated Advisors Network LLC now owns 983 shares of the company’s stock worth $350,000 after purchasing an additional 45 shares during the last quarter. Interchange Capital Partners LLC increased its holdings in shares of Astera Labs by 4.4% during the 3rd quarter. Interchange Capital Partners LLC now owns 1,187 shares of the company’s stock worth $423,000 after purchasing an additional 50 shares during the period. Finally, Glenmede Trust Co. NA increased its holdings in shares of Astera Labs by 2.7% during the 1st quarter. Glenmede Trust Co. NA now owns 1,909 shares of the company’s stock worth $209,000 after purchasing an additional 51 shares during the period. Institutional investors own 60.47% of the company’s stock.

Astera Labs Company Profile

(Get Free Report)

Astera Labs, Inc. is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help move data among processors, accelerators, memory and other components in high-performance computing systems. The company’s portfolio includes Aries PCIe and CXL retimers, Taurus Ethernet smart cable modules, Scorpio fabric switches and Leo CXL memory connectivity controllers. Astera Labs also offers software tools to help customers configure and monitor its connectivity products.